178 related articles for article (PubMed ID: 9289627)
1. [Multiple sclerosis].
Offenhäusser M; Martin R
Med Monatsschr Pharm; 1997 Jun; 20(6):149-57. PubMed ID: 9289627
[No Abstract] [Full Text] [Related]
2. 'Time is brain' also in multiple sclerosis.
Freedman MS
Mult Scler; 2009 Oct; 15(10):1133-4. PubMed ID: 19808740
[No Abstract] [Full Text] [Related]
3. [Multiple sclerosis: from immunopathogenesis to disease management].
Nervenarzt; 1996 Dec; 67(12 Suppl Von Der Im):1-8. PubMed ID: 9403091
[No Abstract] [Full Text] [Related]
4. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease.
Weiner HL
Arch Neurol; 2004 Oct; 61(10):1613-5. PubMed ID: 15477521
[No Abstract] [Full Text] [Related]
5. [Will there soon be a sub-type specific treatment? New approaches to multiple sclerosis therapy].
MMW Fortschr Med; 2008 Apr; 150(15):17. PubMed ID: 18510111
[No Abstract] [Full Text] [Related]
6. Solving the MS puzzle.
Hobson K
US News World Rep; 2002 Oct; 133(13):60-2. PubMed ID: 12375480
[No Abstract] [Full Text] [Related]
7. Treatment of multiple sclerosis and other autoimmune diseases with cladribine.
Beutler E; Sipe J; Romine J; McMillan R; Zyroff J; Koziol J
Semin Hematol; 1996 Jan; 33(1 Suppl 1):45-52. PubMed ID: 8714617
[No Abstract] [Full Text] [Related]
8. [A short history of beta-interferon therapy of multiple sclerosis].
Stock G; Horowski R
Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
[TBL] [Abstract][Full Text] [Related]
9. Disease-modifying drugs for the early treatment of multiple sclerosis.
Flachenecker P
Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
[TBL] [Abstract][Full Text] [Related]
10. [Multiple sclerosis. Biomarkers for deciding treatment].
Meinl E; Voltz R
MMW Fortschr Med; 2004 May; 146 Spec No 2():57-8. PubMed ID: 15376703
[No Abstract] [Full Text] [Related]
11. Treatment of children and adolescents with multiple sclerosis.
Banwell B
Expert Rev Neurother; 2005 May; 5(3):391-401. PubMed ID: 15938672
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of multiple sclerosis].
Simó M
Neuropsychopharmacol Hung; 2009 Mar; 11(1):23-6. PubMed ID: 19731815
[TBL] [Abstract][Full Text] [Related]
13. [Immunosuppressive treatment of multiple sclerosis (review of the literature].
Neretin VIa; Kir'iakov VA; Sapfirova VA
Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(2):119-26. PubMed ID: 2160156
[No Abstract] [Full Text] [Related]
14. [Autoimmune diseases of muscle and nervous system].
Krankenpfl J; 2005; 43(7-10):236. PubMed ID: 16518891
[No Abstract] [Full Text] [Related]
15. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
Giacomini PS; Arnold DL; Bar-Or A; Antel JP
Arch Neurol; 2009 Jan; 66(1):19-20. PubMed ID: 19139295
[No Abstract] [Full Text] [Related]
16. The use of interferon beta in relapsing-remitting multiple sclerosis.
Etheridge LJ; Beverley DW; Ferrie C; McManus E
Arch Dis Child; 2004 Aug; 89(8):789-91. PubMed ID: 15269086
[TBL] [Abstract][Full Text] [Related]
17. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
Gout O
Ann Neurol; 2008 Jan; 63(1):126; author reply 126-7. PubMed ID: 17702028
[No Abstract] [Full Text] [Related]
18. [Pragmatic approach to treatments in multiple sclerosis].
Vermersch P
Rev Neurol (Paris); 2009 Apr; 165 Spec No 2():F125-31. PubMed ID: 19593885
[No Abstract] [Full Text] [Related]
19. [New treatments for multiple sclerosis].
Masdeu JC
Rev Neurol; 1996 Jun; 24(130):708-11. PubMed ID: 8653621
[No Abstract] [Full Text] [Related]
20. [Diagnostics and drug therapy of multiple sclerosis].
Suomen Neurologinen Yhdistys ry
Duodecim; 2002; 118(13):1411-23. PubMed ID: 12239889
[No Abstract] [Full Text] [Related]
[Next] [New Search]
